PatternsRadar
Sign in

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited

NSE
Full chart
107.85INR+3.78 (+3.63%)Close · 6 Oct 2026
14 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹306 CrMarket cap
62.6P/E (TTM)
74.6%Delivery

Filings & corporate actions

21 results filed
CSV
Next results · Q2 FY27
Expected 11 Nov 2026 – 15 Nov 2026
Estimate: filed 42–46 days after quarter end, last 5 times
2026
  • 7 SeptshareholdingShareholding · 6 Aug 2026+1.6%NSE
  • 14 AugresultsResults · Q1 FY27 · standalone+2.0%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+2.0%NSE
  • 30 MayresultsResults · Q4 FY26 · standalone-0.8%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+4.8%NSE
  • 11 FebresultsResults · Q3 FY26 · standalone+4.4%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025+0.3%NSE

Reaction to results · all yearsrose on day 0 in 8 of 21 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026+2.0%-6.9%+17.8%2.1×
Q4 FY2630 May 2026-0.8%+2.5%+15.6%0.7×
Q3 FY2611 Feb 2026+4.4%+5.0%-4.1%2.8×
Q2 FY2614 Nov 2025-0.9%-4.4%-30.7%0.6×
Q1 FY2613 Aug 2025+2.0%-2.3%+11.2%1.1×
Q4 FY2531 May 2025-4.3%+1.0%+25.7%0.3×
Q3 FY2514 Feb 2025-4.7%-8.9%-20.9%2.6×
Q2 FY2514 Nov 2024-0.8%-0.6%+4.4%1.4×
Q1 FY2514 Aug 2024+9.7%+3.8%+18.7%4.6×
Q4 FY2431 May 2024-4.7%-5.9%-2.2%2.0×
Q3 FY2414 Feb 2024+3.9%+3.9%-19.4%1.2×
Q2 FY2411 Nov 2023+1.1%-8.5%-13.1%0.2×
Q1 FY2414 Aug 2023-3.8%-4.2%-0.3%0.6×
Q4 FY2331 May 2023+1.4%+4.9%+16.8%2.3×
Q3 FY238 Feb 2023-3.2%-9.3%-18.5%1.7×
Q2 FY2315 Nov 2022-3.1%-6.5%-3.0%1.0×
Q1 FY2313 Aug 2022-4.2%-4.2%+7.5%1.6×
Q4 FY2231 May 2022-0.4%-2.5%-5.8%0.9×
Q3 FY228 Feb 2022-4.2%-11.9%-16.1%0.6×
Q2 FY2213 Nov 2021+1.0%-2.9%+8.9%1.3×
Q1 FY2211 Aug 2021-1.0%-5.1%-6.6%—
Average-0.5%-3.0%-0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-56.3%
Profit YoY-25.4%
Interest cost YoY-4.8%
Revenue QoQ-76.4%
Profit QoQ-34.3%
CAGR2Y3Y4Y5Y6Y7Y
Revenue-6.2%+6.0%-5.2%———
Profit-3.1%-1.5%-4.3%———

Key data

CSV
Open104.00
Day range101.01 – 108.98
52-week range50.31 – 108.98
From 52w high-1.0%
RSI (14)73.0
ATR (14)4.50
Volume1.84L
Avg volume (20D)2.49L
Rel volume0.74×
Volatility (1Y)50.6%
Turnover₹2.0Cr
SMA 50 / 20090.43 / 78.85

Delivery percentage

Latest · 6 Oct 202674.6%
20-day avg62.8%
1-year avg81.3%
Percentile (own history)51st
Range20.7–100.0%
Sessions1,276

Over the last 20 sessions AAREYDRUGS settled 62.8% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 81.3%, so recent sessions are running 18.5 points lower than usual. The latest session ranks higher than 51% of the 1,276 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.63%+8.36%+14.20%+22.57%+100.80%+37.34%

Valuation

CSV
Market cap₹306 Cr
P/E (TTM)62.6
EPS (TTM)1.72
Shares outstanding2.85Cr
Listed6 Aug 2021

Ownership

CSV
Promoter42.79%
Promoter Δ QoQ+5.08 pp
Public57.21%
FII4.41%
DII1.49%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)84.296.4189.544.6
YoY chg-20.0%-27.9%+75.3%-56.3%
Net profit (₹ Cr)1.01.31.61.0
YoY chg-35.9%+78.0%+231.3%-25.4%
Net margin1.2%1.3%0.8%2.3%
EPS0.720.200.550.36

Shareholding over time

CSV

By quarter

6 Aug 2026 · promoter 42.79% · public 57.21%
30 Sept 2021: promoter 49.38%25 Nov 2021: promoter 48.05%31 Dec 2021: promoter 48.05%31 Mar 2022: promoter 48.06%30 Jun 2022: promoter 50.03%30 Sept 2022: promoter 50.03%31 Dec 2022: promoter 50.03%31 Mar 2023: promoter 50.04%30 Jun 2023: promoter 50.04%30 Sept 2023: promoter 50.04%31 Dec 2023: promoter 50.04%27 Mar 2024: promoter 45.28%31 Mar 2024: promoter 45.28%30 Jun 2024: promoter 45.28%30 Sept 2024: promoter 45.44%31 Dec 2024: promoter 44.80%31 Mar 2025: promoter 44.80%30 Jun 2025: promoter 44.80%30 Sept 2025: promoter 44.80%31 Dec 2025: promoter 39.06%31 Mar 2026: promoter 37.71%30 Jun 2026: promoter 37.71%6 Aug 2026: promoter 42.79%
2021-092026-08
  • Promoter
  • Public and others
Promoter
42.79%
Public
57.21%
Promoter change
+5.08 pp
Filed
7 Sept 2026
FII
4.41%
DII
1.49%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations57.876.5210.4126.9105.1133.8108.1102.284.296.4189.544.6
Other income0.80.35.11.60.00.77.51.60.84.2(0.4)1.7
Total income58.776.8215.5128.5105.2134.5115.6103.885.0100.6189.046.3
Total expenses57.775.3213.3127.2103.4133.1114.0102.083.599.7187.845.8
└ Finance costs1.31.11.21.01.50.92.51.01.30.91.81.7
└ Depreciation0.40.50.40.50.50.6(1.4)0.50.70.80.80.9
Profit before tax1.01.52.11.31.71.41.61.71.50.91.30.5
Tax expense0.20.4(0.0)0.10.10.71.20.40.5(0.4)(0.3)(0.5)
Net profit0.81.02.21.21.60.70.51.41.01.31.61.0
EPS0.310.400.770.881.140.260.040.480.720.200.550.36
Net margin1.36%1.34%1.02%0.98%1.52%0.54%0.43%1.34%1.22%1.33%0.82%2.29%
PBT margin1.74%1.92%1.02%1.05%1.66%1.05%1.50%1.69%1.76%0.96%0.68%1.16%
Tax rate22.07%30.22%-0.27%6.90%8.58%48.70%71.07%20.65%30.92%-38.34%-21.66%-98.55%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

AAREYDRUGS at a glance

  • AAREYDRUGS closed at ₹107.85 on 6 Oct 2026, +3.63% on the day, +37.3% over one year, 1.0% below its 52-week high of ₹108.98.
  • Delivery was 74.6% of traded quantity on 6 Oct 2026, the 51st percentile of its own 1,276 sessions with a reading (20-session average 62.8%, 1-year average 81.3%).
  • Market capitalisation is ₹306 crore at a trailing P/E of 62.6 (trailing EPS ₹1.72).
  • Q1 FY27 results (standalone, filed 14 Aug 2026): revenue ₹45 crore (-56.3% year on year), net profit ₹1 crore (-25.4%); the price moved +2.0% on the first session after.
  • Promoters held 42.79% at 6 Aug 2026, up 5.08 percentage points on the previous filing.
  • Q2 FY27 results are expected between 11 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE198H01019
SeriesEQ
Listed6 Aug 2021
History from6 Aug 2021
Sessions1,280

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE